Payment overview · 2025
General Payments
$4,612.96
199 reported records · 26 companies
Healthcare provider profile · identity verified
Wu Tan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FLUSHING, NY · NPI 1518236181
Verified facts
What the public records show
CMS Open Payments records show Wu Tan, MD received $4,612.96 in general payments during 2025 across 199 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 9.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Caplyta, Creon, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Nurtec Odt, Ozempic, Prolia, Qulipta, Rexulti, Rybelsus, Shingrix, Trelegy Ellipta, Ubrelvy, Verquvo, Vraylar, Xifaxan, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HUMIRA as an associated drug or biological on 1828 records involving 689 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Humira by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 743 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 321 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 925 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 297 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 734 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 431 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 500 claims for Nexlizet by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Trelegy Ellipta by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Caplyta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Rexulti by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Verquvo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 431 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Gemtesa by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $439.64 | 9.5% | 13 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $391.18 | 8.5% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $327.67 | 7.1% | 16 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $317.45 | 6.9% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $316.23 | 6.9% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $293.22 | 6.4% | 14 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $274.97 | 6.0% | 11 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $244.26 | 5.3% | 15 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $237.20 | 5.1% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $229.30 | 5.0% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $210.84 | 4.6% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $176.47 | 3.8% | 11 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $170.92 | 3.7% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $164.46 | 3.6% | 7 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $159.23 | 3.5% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $156.20 | 3.4% | 6 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $118.74 | 2.6% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $94.01 | 2.0% | 5 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $83.87 | 1.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.01 | 1.0% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $42.48 | 0.9% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.72 | 0.6% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $26.14 | 0.6% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.99 | 0.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.70 | 0.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.06 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,501.51 | 198 |
| Education | $111.45 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $554.65 | 19 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $391.18 | 17 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $316.23 | 15 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $274.97 | 11 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $270.29 | 10 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $244.26 | 15 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $210.84 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $210.84 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $204.52 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $204.34 | 9 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $170.92 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $164.46 | 7 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $159.23 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $156.20 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $128.58 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $94.01 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $93.31 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $91.17 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $85.30 | 6 | 2025 |
Source payment records
|
|||||
| NEMLUVIO Normalized: nemluvio |
Drug | Galderma Laboratories, L.P. | $78.09 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $65.97 | 3 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $57.90 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $54.02 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $52.97 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $46.12 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $46.01 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $42.48 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $40.76 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.50 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $30.21 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $29.85 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $28.38 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $26.72 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $8.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 151 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 925 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 77 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 734 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 297 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 743 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 36 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 106 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 190 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 36 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 66 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 56 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 191 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 15 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 45 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 60 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
151 | 63 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | HUMIRA open payments reported associated product |
CMS Open Payments — General Payments 1828 supporting records · 689 recipient NPIs · example record 1201353784 |
Humira · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
743 | 144 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
36 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
321 | 38 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
15 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
190 | 142 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
925 | 144 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
297 | 62 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
734 | 118 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
431 | 81 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
500 | 92 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
154 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
112 | 110 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
56 | 44 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
191 | 58 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
66 | 15 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
106 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
66 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
37 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
431 | 81 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
36 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
77 | 18 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 3024 | 407 |
| Amlodipine Besylate | Amlodipine Besylate | 2288 | 278 |
| Losartan Potassium | Losartan Potassium | 2174 | 292 |
| Tamsulosin Hcl | Tamsulosin Hcl | 1617 | 222 |
| Metoprolol Succinate | Metoprolol Succinate | 1482 | 211 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1199 | 150 |
| Donepezil Hcl | Donepezil Hcl | 1140 | 186 |
| Famotidine | Famotidine | 989 | 194 |
| Farxiga | Dapagliflozin Propanediol | 925 | 144 |
| Metformin Hcl Er | Metformin Hcl | 921 | 146 |
| Diclofenac Epolamine | Diclofenac Epolamine | 855 | 172 |
| Finasteride | Finasteride | 832 | 122 |
| Linzess | Linaclotide | 743 | 144 |
| Jardiance | Empagliflozin | 734 | 118 |
| Metformin Hcl | Metformin Hcl | 733 | 99 |
| Alendronate Sodium | Alendronate Sodium | 730 | 148 |
| Montelukast Sodium | Montelukast Sodium | 693 | 149 |
| Fluticasone Propionate | Fluticasone Propionate | 673 | 260 |
| Allopurinol | Allopurinol | 667 | 102 |
| Ropinirole Hcl | Ropinirole Hcl | 656 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 652 | 75 |
| Mirtazapine | Mirtazapine | 651 | 63 |
| Gabapentin | Gabapentin | 626 | 124 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 587 | 77 |
| Celecoxib | Celecoxib | 581 | 293 |
| Dutasteride | Dutasteride | 561 | 68 |
| Ezetimibe | Ezetimibe | 508 | 92 |
| Telmisartan | Telmisartan | 505 | 62 |
| Myrbetriq | Mirabegron | 500 | 77 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 500 | 92 |
| Pioglitazone Hcl | Pioglitazone Hcl | 470 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 468 | 68 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 455 | 59 |
| Omeprazole | Omeprazole | 445 | 169 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 437 | 42 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 436 | 113 |
| Eliquis | Apixaban | 431 | 81 |
| Memantine Hcl | Memantine Hcl | 422 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 421 | 134 |
| Nifedipine Er | Nifedipine | 418 | 49 |
| Xarelto | Rivaroxaban | 407 | 51 |
| Diclofenac Sodium | Diclofenac Sodium | 402 | 198 |
| Lactulose | Lactulose | 371 | 88 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 366 | 46 |
| Azelastine Hcl | Azelastine Hcl | 357 | 132 |
| Clopidogrel | Clopidogrel Bisulfate | 357 | 61 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 344 | 44 |
| Colchicine | Colchicine | 339 | 68 |
| Quetiapine Fumarate | Quetiapine Fumarate | 321 | 48 |
| Synthroid | Levothyroxine Sodium | 321 | 38 |
| Meclizine Hcl | Meclizine Hcl | 318 | 155 |
| Furosemide | Furosemide | 317 | 55 |
| Clonazepam | Clonazepam | 312 | 66 |
| Memantine Hcl Er | Memantine Hcl | 307 | 39 |
| Kerendia | Finerenone | 297 | 62 |
| Labetalol Hcl | Labetalol Hcl | 269 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 265 | 143 |
| Halobetasol Propionate | Halobetasol Propionate | 259 | 146 |
| Folic Acid | Folic Acid | 251 | 50 |
| Divalproex Sodium | Divalproex Sodium | 232 | 25 |
| Carvedilol | Carvedilol | 220 | 35 |
| Nebivolol Hcl | Nebivolol Hcl | 218 | 29 |
| Ammonium Lactate | Ammonium Lactate | 215 | 132 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 212 | 155 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 210 | 84 |
| Entresto | Sacubitril/Valsartan | 195 | 32 |
| Levetiracetam | Levetiracetam | 195 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 191 | 58 |
| Prolia | Denosumab | 190 | 142 |
| Amantadine | Amantadine Hcl | 184 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 184 | 20 |
| Januvia | Sitagliptin Phosphate | 184 | 26 |
| Spironolactone | Spironolactone | 179 | 37 |
| Vascepa | Icosapent Ethyl | 178 | 88 |
| Glipizide Er | Glipizide | 173 | 28 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 159 | 134 |
| Livalo | Pitavastatin Calcium | 158 | 31 |
| Trazodone Hcl | Trazodone Hcl | 157 | 22 |
| Azithromycin | Azithromycin | 155 | 113 |
| Mometasone Furoate | Mometasone Furoate | 154 | 65 |
| Vemlidy | Tenofovir Alafenamide | 154 | 16 |
| Dapagliflozin | Dapagliflozin Propanediol | 153 | 67 |
| Creon | Lipase/Protease/Amylase | 151 | 63 |
| Ibuprofen | Ibuprofen | 149 | 81 |
| Clobetasol Propionate | Clobetasol Propionate | 146 | 82 |
| Latanoprost | Latanoprost | 146 | 23 |
| Lisinopril | Lisinopril | 146 | 21 |
| Cilostazol | Cilostazol | 145 | suppressed |
| Entecavir | Entecavir | 145 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 142 | 39 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 142 | 58 |
| Mupirocin | Mupirocin | 141 | 78 |
| Loperamide | Loperamide Hcl | 140 | 45 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 139 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 139 | 78 |
| Dupixent Syringe | Dupilumab | 135 | 63 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 133 | 21 |
| Terazosin Hcl | Terazosin Hcl | 128 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 125 | 38 |
| Scopolamine | Scopolamine | 124 | 35 |
| Fenofibrate | Fenofibrate,micronized | 123 | 18 |
| Levofloxacin | Levofloxacin | 123 | 106 |
| Hydralazine Hcl | Hydralazine Hcl | 121 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 118 | 39 |
| Doxycycline Hyclate | Doxycycline Hyclate | 116 | 87 |
| Torsemide | Torsemide | 114 | 28 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 112 | 110 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 111 | 27 |
| Hydrocortisone | Hydrocortisone | 111 | 55 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 109 | 17 |
| Lorazepam | Lorazepam | 109 | 19 |
| Ranolazine Er | Ranolazine | 109 | 15 |
| Prednisone | Prednisone | 108 | 61 |
| Sucralfate | Sucralfate | 107 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 106 | 19 |
| Ozempic | Semaglutide | 106 | 30 |
| Methenamine Hippurate | Methenamine Hippurate | 105 | 14 |
| Alcohol Pads | Alcohol Antiseptic Pads | 103 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 99 | 13 |
| Potassium Chloride | Potassium Chloride | 98 | 30 |
| Tramadol Hcl | Tramadol Hcl | 97 | 51 |
| Entacapone | Entacapone | 96 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 95 | 48 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 95 | 35 |
| Dicyclomine Hcl | Dicyclomine Hcl | 94 | 62 |
| Tradjenta | Linagliptin | 90 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 90 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 58 |
| Methimazole | Methimazole | 89 | suppressed |
| Baclofen | Baclofen | 87 | 20 |
| Sertraline Hcl | Sertraline Hcl | 85 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 83 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 19 |
| Ketoconazole | Ketoconazole | 78 | 38 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 78 | 68 |
| Repatha Sureclick | Evolocumab | 78 | 27 |
| Gemtesa | Vibegron | 77 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 76 | suppressed |
| Silodosin | Silodosin | 76 | suppressed |
| Digoxin | Digoxin | 74 | suppressed |
| Mounjaro | Tirzepatide | 74 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 74 | 22 |
| Valacyclovir | Valacyclovir Hcl | 74 | 34 |
| Nitroglycerin | Nitroglycerin | 72 | 47 |
| Restasis | Cyclosporine | 71 | 30 |
| Candesartan Cilexetil | Candesartan Cilexetil | 68 | suppressed |
| Febuxostat | Febuxostat | 66 | suppressed |
| Metronidazole | Metronidazole | 66 | 53 |
| Rexulti | Brexpiprazole | 66 | 15 |
| Bepotastine Besilate | Bepotastine Besilate | 65 | 25 |
| Belsomra | Suvorexant | 64 | 36 |
| Pregabalin | Pregabalin | 63 | 17 |
| Procto-Med Hc | Hydrocortisone | 63 | 37 |
| Tadalafil | Tadalafil | 63 | 14 |
| Tacrolimus | Tacrolimus | 62 | 38 |
| Propranolol Hcl | Propranolol Hcl | 60 | suppressed |
| Risperidone | Risperidone | 60 | suppressed |
| Xifaxan | Rifaximin | 60 | 15 |
| Pitavastatin Calcium | Pitavastatin Calcium | 59 | 23 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 57 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 31 |
| Fenofibrate | Fenofibrate | 56 | suppressed |
| Quviviq | Daridorexant Hcl | 56 | 35 |
| Rybelsus | Semaglutide | 56 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 56 | 44 |
| Nystatin | Nystatin | 55 | 23 |
| Chlorthalidone | Chlorthalidone | 54 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 53 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 16 |
| Retacrit | Epoetin Alfa-Epbx | 53 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 50 | 17 |
| Timolol Maleate | Timolol Maleate | 50 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 49 | suppressed |
| Amoxicillin | Amoxicillin | 47 | 41 |
| Atenolol | Atenolol | 47 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 42 |
| Midodrine Hcl | Midodrine Hcl | 46 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 46 | 16 |
| Alprazolam | Alprazolam | 45 | 28 |
| Trulance | Plecanatide | 45 | suppressed |
| Verquvo | Vericiguat | 45 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 43 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 42 | 35 |
| Pilocarpine Hcl | Pilocarpine Hcl | 42 | 13 |
| Licart | Diclofenac Epolamine | 41 | suppressed |
| Meloxicam | Meloxicam | 41 | 17 |
| Cyclosporine | Cyclosporine | 40 | 19 |
| Praluent Pen | Alirocumab | 40 | 12 |
| Procrit | Epoetin Alfa | 40 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 40 | suppressed |
| Mirabegron Er | Mirabegron | 39 | 22 |
| Nystop | Nystatin | 39 | 14 |
| Rinvoq | Upadacitinib | 39 | suppressed |
| Novolog Flexpen | Insulin Aspart | 38 | 16 |
| Oxcarbazepine | Oxcarbazepine | 38 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 37 | 35 |
| Sevelamer Carbonate | Sevelamer Carbonate | 37 | suppressed |
| Modafinil | Modafinil | 36 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 36 | 14 |
| Potassium Citrate Er | Potassium Citrate | 36 | suppressed |
| Qulipta | Atogepant | 36 | 21 |
| Repatha Syringe | Evolocumab | 36 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 35 | 12 |
| Bupropion Hcl | Bupropion Hcl | 34 | suppressed |
| Lamotrigine | Lamotrigine | 34 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Valsartan | Valsartan | 34 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 33 | 11 |
| Lokelma | Sodium Zirconium Cyclosilicate | 32 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Ciclopirox | Ciclopirox | 31 | suppressed |
| Levemir Flexpen | Insulin Detemir | 31 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Olanzapine | Olanzapine | 30 | suppressed |
| Proctozone-Hc | Hydrocortisone | 30 | 17 |
| Terbinafine Hcl | Terbinafine Hcl | 30 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 29 | suppressed |
| Clemastine Fumarate | Clemastine Fumarate | 29 | 15 |
| Doxepin Hcl | Doxepin Hcl | 29 | 16 |
| Irbesartan | Irbesartan | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 29 | 21 |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Calcium Acetate | Calcium Acetate | 27 | suppressed |
| Enulose | Lactulose | 26 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 22 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Calcitriol | Calcitriol | 25 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 25 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 25 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 25 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 24 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 22 | 17 |
| Nitroglycerin Patch | Nitroglycerin | 22 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 22 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 22 | 14 |
| Theophylline Er | Theophylline Anhydrous | 22 | suppressed |
| Tobramycin | Tobramycin | 22 | 17 |
| Admelog Solostar | Insulin Lispro | 21 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 21 | suppressed |
| Clotrimazole | Clotrimazole | 21 | 14 |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 21 | 15 |
| Humira | Adalimumab | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 20 | 13 |
| Estradiol | Estradiol | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Caplyta | Lumateperone Tosylate | 19 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 19 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Vyzulta | Latanoprostene Bunod | 19 | suppressed |
| Austedo Xr | Deutetrabenazine | 18 | suppressed |
| Meropenem | Meropenem | 18 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Roflumilast | Roflumilast | 17 | suppressed |
| Alogliptin-Metformin | Alogliptin Benz/Metformin Hcl | 16 | suppressed |
| Bicalutamide | Bicalutamide | 16 | suppressed |
| Levetiracetam Er | Levetiracetam | 16 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Vilazodone Hcl | Vilazodone Hcl | 16 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 15 | 14 |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Ubrelvy | Ubrogepant | 15 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 14 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | 11 |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 13 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Motegrity | Prucalopride Succinate | 13 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Restasis Multidose | Cyclosporine | 12 | suppressed |
| Rifampin | Rifampin | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Cyltezo(Cf) | Adalimumab-Adbm | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Levobunolol Hcl | Levobunolol Hcl | 11 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 11 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,612.96 · 199 records | Teva Pharmaceuticals USA, Inc. | AIRSUPRA, AMVUTTRA, ARISTADA, AUSTEDO XR, BREZTRI, CAPLYTA, CAPVAXIVE, COBENFY, CREON, DUPIXENT, EVENITY, FANAPT, FARXIGA, GEMTESA, IBSRELA, JARDIANCE, Kerendia, LINZESS, LYBALVI, NEMLUVIO, NEXLETOL, NURTEC ODT, Ozempic, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, UZEDY, VERQUVO, VOWST, VRAYLAR, VYALEV, XIFAXAN, ZAVZPRET, ZENPEP | 34 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error